Placeholder Banner

BIO Comments on Draft Guidance: Q13 Continuous Manufacturing of Drug Substances and Drug Products

December 13, 2021

On Monday, December 13th, BIO submitted comments to the Food and Drug Administration’s recent draft guidance for industry entitled, Q13 Continuous Manufacturing of Drug Substances and Drug Products. The draft guidance was prepared under the auspices of the International Council for Harmonisation (ICH) and provides clarification on continuous manufacturing (CM) concepts and describes scientific approaches and regulatory considerations specific to CM of drug substances and drug products. According to the Agency, the draft guidance is intended to provide scientific and regulatory considerations for the development, implementation, operation, and lifecycle management of CM. In the comments submitted, BIO recommended the inclusion of additional terms in the guidance’s glossary, offered suggestions of where it might be helpful for the Agency to include specific examples, and requested the revision or addition of language to further clarify a handful of key points.

Download Full Comments Below
BIO Comments on Draft Guidance: Q13 Continuous Manufacturing of Drug Substances and Drug Products
Discover More
On Wednesday, December 29th, BIO submitted comments to the Food and Drug Administration’s recent draft guidance for industry entitled, Reporting Amount of Listed Drugs and Biological Products Under Section 510(j)(3) of the Federal Food, Drug, and…
On Monday, November 29th, BIO submitted comments in response to a recent FDA draft guidance for industry clarifying how considerations about a drug’s benefits, risks, and risk management options factor into certain premarket and postmarket…
On Monday, November 8th, BIO submitted comments to the FDA’s draft guidance on Nonclinical Biodistribution Considerations for Gene Therapy Products. In the comment letter, BIO expressed appreciation for the Agency’s decision to put forth a draft…